CytoSorbents, Inc.

257 articles with CytoSorbents, Inc.

• CytoSorbents to Present at the 21st Annual BIO CEO & Investor Conference

  2/5/2019

  CytoSorbents Corporation announced that its Chief Executive Officer, Dr.

• CytoSorbents Announces the Data Safety Monitoring Board Recommends Continuation of REMOVE Endocarditis Trial

  2/4/2019

  CytoSorbents Corporation announced that the Data Safety Monitoring Board of the German government-funded REMOVE Endocarditis trial recommended continuation of the study following an interim analysis on the first 50 patients of the study.

• CytoSorbents Announces Expansion of CytoSorb® Partnership with Fresenius Medical Care

  1/22/2019

  Agreement brings innovative CytoSorb® therapy to Korea and Mexico and sets the stage for future growth   [22-January-2019]   MONMOUTH JUNCTION, N.J. , Jan. 22, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its  CytoSorb®  blood purification technology to treat deadly inflammation in critically-ill and ca

• CytoSorbents Issues Stockholder Letter with Preliminary 2018 Financial Results

  1/7/2019

  CytoSorbents achieved another year of record growth with total revenue of more than $22.3 million, including product sales of approximately $20.2 million, a 51% increase from a year ago   [07-January-2019]   MONMOUTH JUNCTION, N.J. , Jan. 7, 2019 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb

• CytoSorbents To Highlight Progress at Biotech Showcase 2019

  1/4/2019

  CytoSorbents Corporation announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will provide a corporate update and highlight the company's progress at the Biotech Showcase 2019 conference on Monday, January 7, 2019 at 10:30 AM PST in San Francisco, California

• CytoSorbents to Present at the 30th Annual Piper Jaffray Healthcare Conference

  11/26/2018

  CytoSorbents Corporation will present an overview of the company at the 30th Annual Piper Jaffray Healthcare Conference in New York City on November 29, 2018. 

• CytoSorbents Recognized Again as One of the Fastest Growing Companies in North America on Deloitte's 2018 Technology Fast 500™

  11/19/2018

  Strong international demand for the Company's CytoSorb blood purification technology to control deadly inflammation drives 267% revenue growth over the past three years

• CytoSorbents to Report Q3 2018 Operating and Financial Results

  10/31/2018

  CytoSorbents Corporation will report Q3 2018 financial results after the market close on Tuesday, November 6, 2018. 

• CytoSorbents to Showcase CytoSorb® at Two Key European Medical Conferences

  10/18/2018

  CytoSorbents, Inc. (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it will showcase CytoSorb at the 32nd European Association for CardioThoracic Surgery Conference (EACTS) in Milan, Italy from October 18-20, 2018, and the 31st European Society of Intensive Care Medicine Congress (ESICM) in Paris, France from October 20-24, 2018.

• CytoSorbents to Present at the Cantor Fitzgerald Global Healthcare Conference

  10/3/2018

  Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company at the Cantor Fitzgerald Global Healthcare Conference today in New York City at the InterContinental New York Barclay Hotel.    

• CytoSorb® Assigned Dedicated Procedure Code in Switzerland

  9/20/2018

  Dedicated procedure code for cytokine reduction from the Swiss Federal Statistical Office, a division of the Federal Department of Home Affairs in Switzerland, will become effective January 1, 2019.

• World Sepsis Day 2018: CytoSorbents Sponsors the Sepsis Heroes Gala and the Roger Bone Award for Excellence in Sepsis Research

  9/13/2018

  CytoSorbents Corporation commemorates World Sepsis Day 2018 today as a sponsor of the Sepsis Heroes Gala and the Roger Bone Award for Excellence in Sepsis Research.

• CytoSorbents REFRESH 2-AKI Protocol Amendment Approved by FDA

  9/4/2018

  CytoSorbents Corporation announced that the REFRESH 2-AKI trial protocol amendment that was discussed in the August 2, 2018 earnings press release, has now been approved by the U.S. Food and Drug Administration (FDA).

• CytoSorbents to Present at the B. Riley FBR Healthcare Conference and the H.C. Wainwright 20th Annual Global Investment Conference

  8/28/2018

  Conference in New York City on Tuesday, September 4, 2018 at the New York Marriott East Side Hotel

• CytoSorbents Awarded up to $3M in SBIR Phase IIB Bridge Funding by NIH/NHLBI to Accelerate U.S. Approval and Commercialization of the HemoDefend™ Blood Transfusion Filter

  8/21/2018

  CytoSorbents Corporation (Nasdaq: CTSO) a critical care immunotherapy leader specializing in blood purification, announced today that the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), has awarded the company a three-year Phase IIB Bridge SBIR (Small Business Innovation Research) award

• CytoSorbents Achieves Record Total Revenue and CytoSorb Sales in the Second Quarter 2018

  8/2/2018

  Quarterly CytoSorb Sales Reach $5.2 Million, With Trailing 12-month CytoSorb Sales of $17.4 Million

• CytoSorbents Expands Distribution of CytoSorb® to a Total of 53 Countries Worldwide

  7/31/2018

  CytoSorbents Corporation, announced that it has expanded the distribution of CytoSorb® to a total of 53 countries worldwide.

• CytoSorbents to Report Q2 2018 Operating and Financial Results

  7/26/2018

  CytoSorbents Corporation will report Q2 2018 financial results after the market close on Thursday, August 2, 2018.

• Aferetica and CytoSorbents Debut the PerLife™ System for Organ Preservation and Rehabilitation at the 27th International Congress of the Transplantation Society

  7/9/2018

  PerLife™ Is the First System Integrating a Sorbent Purification Technology to Perfuse, Cleanse, Recondition, and Preserve Harvested Solid Organs for Transplantation

• CytoSorbents Officially Opens New U.S. CytoSorb Manufacturing Facility

  6/12/2018

  New facility quadruples production capacity and is expected to accelerate margin expansion and drive operating profitability